Clinical Trial – Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer - Kidney Cancer

H. Lee Moffitt Cancer Center and Research Institute is running a clinical trial to test drugs called Pembrolizumab and Interleukin-2. The main purpose of this study is to evaluate the effects of the interleukin-2 given in combination with pembrolizumab. Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™. Pembrolizumab is also called Keytruda™, or anti-PD-1 antibody.

The drug is Pembrolizumab and Interleukin-2.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Actual Study Start Date : April 11, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2019

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.